Recruiting Breast Cancer Studies in Mesa
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people wi...
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effec...
About Breast Cancer Clinical Trials in Mesa
Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.
There are currently 2 breast cancer clinical trials recruiting participants in Mesa, AZ. These studies are seeking a combined 1,520 participants. Research is being sponsored by Pfizer, American Society of Clinical Oncology. Clinical trial participation is free and participants receive study-related medical care at no cost.
Breast Cancer Clinical Trials in Mesa — FAQ
Are there breast cancer clinical trials in Mesa?
Yes, there are 2 breast cancer clinical trials currently recruiting in Mesa, AZ. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Mesa?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Mesa research site will contact you about next steps.
Are clinical trials in Mesa free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Mesa studies also compensate for your time and travel.
What breast cancer treatments are being tested?
The 2 active trials in Mesa are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.
Data updated March 2, 2026 from ClinicalTrials.gov